icosapent ethyl / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 26 Diseases   6 Trials   6 Trials   4342 News 


«12...1920212223242526272829...5051»
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Clinical, Journal:  REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES]). (Pubmed Central) -  Dec 1, 2020   
    The reduction of cardiovascular events with icosapent ethyl-intervention (REDUCE-IT) trial showed in persons with prior cardiovascular disease (CVD) or diabetes mellitus (DM) that icosapent ethyl (IPE) reduced CVD events by 25%...Using FDA eligibility criteria, an estimated 4.6 million persons would be eligible for IPE, with 60,544 preventable primary CVD outcomes annually from REDUCE-IT USA event rates. In conclusion, many CVD events in US adults with known CVD or DM and well-controlled LDL-C on statin therapy can be prevented with IPE.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer (clinicaltrials.gov) -  Dec 1, 2020   
    P2,  N=2, Terminated, 
    In conclusion, many CVD events in US adults with known CVD or DM and well-controlled LDL-C on statin therapy can be prevented with IPE. N=96 --> 2 | Trial completion date: Mar 2022 --> Nov 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2022 --> Nov 2020; PI is requesting termination (closure) of this study.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Enrollment open, Enrollment change:  PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial (clinicaltrials.gov) -  Nov 23, 2020   
    P3,  N=2000, Recruiting, 
    N=96 --> 2 | Trial completion date: Mar 2022 --> Nov 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2022 --> Nov 2020; PI is requesting termination (closure) of this study. Not yet recruiting --> Recruiting | N=1500 --> 2000
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Review, Journal:  Cardiovascular Risk Reduction With Icosapent Ethyl: A Systematic Literature Review. (Pubmed Central) -  Nov 19, 2020   
    This literature review will explain the reduction of cardiovascular risks with icosapent ethyl. Though some genetic conditions can cause some of these ailments, the rest of the predisposing conditions revolve around cholesterol, lipoproteins, and triglycerides.
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Stat news hates Vascepa (Twitter) -  Nov 16, 2020